Intelligence · Clinical pipeline
Oncology · Phase III
Oncology programs at Phase III — ClinicalTrials.gov pipeline intelligence.
Quick answer
Oncology Phase III programs: NovaPharmaNews indexes 1,266 matching clinical development programs from ClinicalTrials.gov with sponsor, modality, and NCT cross-links.
Top sponsors
- AstraZeneca 75 programs
- Chinese Academy of 70 programs
- HOFFMANN-LA ROCHE 68 programs
- MSD Merck Sharp 56 programs
- First People's Hospital 53 programs
- Ningbo Cancer Hospital 44 programs
- United Therapeutics Europe 43 programs
- Anaxis Pharma 37 programs
- AstraZeneca 37 programs
- Novartis India 32 programs
- George Institute for 29 programs
- Takeda 28 programs
Pipeline programs
-
CA209-8HW
Bristol-Myers Squibb Australia Pty Ltd
Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient Metastatic Colorectal Cancer (dMMR)
1 trial -
CA209-8Y8
Bristol-Myers Squibb Australia Pty Ltd
Advanced Renal Cell Carcinoma with Intermediate- or Poor-Risk Factors
1 trial -
CA209-901
Bristol-Myers Squibb Australia Pty Ltd
Untreated Unresectable or Metastatic Urothelial Cancer
1 trial -
CA209-9DW
Bristol-Myers Squibb Australia Pty Ltd
Hepatocellular Carcinoma, Hepatocellular Carcinoma, Hepatocellular Carcinoma, Hepatocellular Carcinoma
1 trial -
CA209-9DX
Bristol-Myers Squibb Australia Pty Ltd
Hepatocellular Carcinoma
1 trial -
CA209-9ER
Bristol-Myers Squibb Australia Pty Ltd
Advanced or Metastatic Renal Cell Carcinoma
1 trial -
CA209-9LA
Bristol-Myers Squibb Australia Pty Ltd
Stage IV Non-Small Cell Lung Cancer (NSCLC)
1 trial -
CA224-047
Bristol-Myers Squibb Australia Pty Ltd
Previously Untreated Metastatic or Unresectable Melanoma
1 trial -
CA224-098
Bristol-Myers Squibb Australia Pty Ltd
Participants with completely resected Stage III or Stage IV melanoma
1 trial -
CA224-123
Bristol-Myers Squibb Australia Pty Ltd
Metastatic Colorectal Cancer
1 trial -
CA2241093
Bristol-Myers Squibb Australia Pty Ltd
Non-squamous (NSQ), Stage IV or Recurrent Non-small Cell Lung Cancer
1 trial -
CA239-0004
Bristol-Myers Squibb Australia Pty Ltd
Locally Advanced or Metastatic Non-small Cell Lung Cancer
1 trial -
CA240-0029
Bristol-Myers Squibb Australia Pty Ltd
metastatic non-small cell lung cancer
1 trial -
CA240-0030
Bristol-Myers Squibb Australia Pty Ltd
Untreated Metastatic Pancreatic Ductal Adenocarcinoma
1 trial -
CA244-0008
Bristol-Myers Squibb Australia Pty Ltd
Breast cancer, Triple-negative breast cancer
1 trial -
CA244-0010
Bristol-Myers Squibb Australia Pty Ltd
EGFR-mutated Non-small Cell Lung Cancer
1 trial -
CA2440012
Bristol-Myers Squibb Australia Pty Ltd
Metastatic urothelial cancer
1 trial -
CA245-0001
Bristol-Myers Squibb Australia Pty Ltd
Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
1 trial -
CA2660001
Bristol-Myers Squibb Australia Pty Ltd
Unresectable Stage III non-small cell lung cancer without progression
1 trial -
CA2660002
Bristol-Myers Squibb Australia Pty Ltd
Non-Small Cell Lung Cancer
1 trial -
CA2660003
Bristol-Myers Squibb Australia Pty Ltd
Untreated, Unresectable or Metastatic Colorectal Cancer
1 trial -
CA2660004
Bristol-Myers Squibb Australia Pty Ltd
Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
1 trial -
CAAA601A62301
Novartis Pharmaceuticals
Gastroenteropancreatic neuroendocrine tumor (GEP-NET)
1 trial -
CAAA617B12302
Novartis Pharmaceuticals
PSMA-positive metastatic castration-resistant prostate cancer
1 trial -
CAAA617C12301
Novartis Pharmaceuticals
PSMA-positive metastatic hormone-sensitive prostate cancer (mHSPC)
1 trial -
CAAA617D12302
Novartis Pharmaceuticals
Oligometastatic prostate cancer (OMPC)
1 trial -
CABAZITAXEL
Sanofi Pasteur
Prostate Cancer Metastatic
1 trial -
CABL001A2001B
Novartis Pharmaceuticals
chronic myelogenous leukemia (CML) or Philadelphia Chromosome positive acute lymphoblastic leukemia (Ph+ ALL)
1 trial -
CABL001J12301
Novartis Pharmaceuticals
Chronic Myeloid Leukemia
1 trial -
CABL001J12302
Novartis Pharmaceuticals
Chronic Myeloid Leukemia
1 trial -
CANAKINUMAB, PEMETREXED
Novartis Pharmaceuticals
Non-small cell lung cancer
1 trial -
CAPECITABINE
Disc Medicine
Salivary Duct Carcinoma
1 trial -
CAPECITABINE for Locally advanced stage II/III rectal cancer
Fondazione Telethon ETS
Locally advanced stage II/III rectal cancer
1 trial -
CBYL719C2303
Novartis Pharmaceuticals
Hormone receptor positive, HER2-negative advanced breast cancer
1 trial -
CBYL719K12301
Novartis Pharmaceuticals
Platinum-resistant or refractory, high-grade serous ovarian cancer with no germline BRCA mutation
1 trial -
CCTL019H2301
Novartis Pharmaceuticals
Adult patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma
1 trial -
CETUXIMAB
Disc Medicine
oral squamous cell carcinoma
1 trial -
CG0070 Adenovirus Vector
CG Oncology
Transitional Cell Carcinoma
1 trial -
CGT9486 plus sunitinib
Cogent Biosciences
Advanced Gastrointestinal Stromal Tumors
1 trial -
CISPLATIN
Ningbo Cancer Hospital
Ovarian epithelial cancer : intraperitoneal resectable relapse
1 trial -
CISPLATIN, CARBOPLATIN
Cardiff Oncology
Human papillomavirus (HPV)-positive oropharyngeal cancer
1 trial -
CJDQ443B12301
Novartis Pharmaceuticals
Advanced non-small cell lung cancer harboring the KRAS G12C mutation
1 trial -
CL3-95005-006
The George Institute
Metastatic colorectal cancer
1 trial -
CL3-95031-007
The George Institute
Locally advanced or metastatic conventional chondrosarcoma with an IDH1 mutation, untreated or previously treated with 1 or 2 systemic treatment regimens
1 trial -
CLEE011O12001
Novartis Pharmaceuticals
HR-positive HER-2- negative Breast Cancer
1 trial -
CLEE011O12301C
Novartis Pharmaceuticals
hormone receptor (HR)-positive, HER2-negative, early breast cancer (EBC).
1 trial -
CLIN2001UCM301
STEBA Biotech S.A
Low Grade Upper Tract Urothelial Cancer
1 trial -
CMF regimen
United Therapeutics Europe Ltd
Breast Cancer
2 trials
Frequently asked questions
How many oncology Phase III programs exist?
1,266 programs match both the therapeutic area and stage filters in our published index.